| AGENUS INC. DL-,01 |
| USA |
| Gesundheit |
| US00847G8042 / A403RK |
| AJ8 (Frankfurt) / AGEN (NASDAQ) |
| FRA:AJ8, ETR:AJ8, AJ8:GR, NASDAQ:AGEN |
| - |
| https://agenusbio.com/ |
|
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune syste..
>Volltext.. |
| 276.27 Mio. EUR |
| 438.88 Mio. EUR |
| 121.52 Mio. EUR |
| 49.32 Mio. EUR |
| 26.92 Mio. EUR |
| 0.67 EUR |
| 251.67 Mio. EUR |
| 60.73 Mio. EUR |
| -94.23 Mio. EUR |
| 0.43 |
| 29.88% |
| - |
| - |
| - |
| - |
| - |
| AGENUS |
| 17.11.26 |
|
||||
|